Correction: DanCann Pharma A/S intends to initiate and complete a partly secured rights issue of up to DKK 18.5 million to restructure, strengthen and secure a debt-free capital structure
Correction to the press release issued yesterday: The previous press release incorrectly stated that underwriters had been secured for DKK 11 million. This has now been corrected to DKK 12.5 million. COPENHAGEN, Denmark, 29 March 2024 – DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, intends to resolve on a new issue of shares with pre-emptive subscription rights for the Company's existing shareholders of up to approx. DKK 18.5 million before transaction costs (the "Rights Issue"). The Company will call for an extraordinary